Literature DB >> 15116325

Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14).

James R Cook1, Nadine Ives Aguilera, Shalini Reshmi-Skarja, Xin Huang, Zhisheng Yu, Susanne M Gollin, Susan L Abbondanzo, Steven H Swerdlow.   

Abstract

A t(9;14)(p13;q32) involving the PAX5 and IGH genes has been described in association with lymphoplasmacytic lymphoma. Although often described as common, the incidence of this translocation in nodal lymphoplasmacytic lymphoma has never been investigated. Recent studies of patients with Waldenström's macroglobulinemia (often corresponding to marrow-based lymphoplasmacytic lymphoma) have failed to identify the t(9;14). These studies have suggested that either nodal and marrow-based lymphoplasmacytic lymphomas have distinct pathogenetic mechanisms or that the t(9;14) is less frequent in lymphoplasmacytic lymphoma than was believed previously. We therefore analyzed a series of nodal or other extramedullary lymphoplasmacytic lymphomas for the presence of the t(9;14) with paraffin section interphase fluorescence in situ hybridization. We developed a BAC contig probe spanning all previously described PAX5 breakpoints and validated this assay with the KIS-1 cell line that expresses a t(9;14). Analysis with the PAX5 probe showed a lack of PAX5 rearrangements in all cases that were analyzed successfully. Similarly, analysis by an IGH fluorescence in situ hybridization probe showed no evidence of translocations involving the IGH locus. These findings indicate that the t(9;14) is at least uncommon in lymphoplasmacytic lymphoma and should no longer be considered a characteristic finding in this type of lymphoma as defined by World Health Organization criteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15116325     DOI: 10.1016/j.humpath.2003.10.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases.

Authors:  Shannon Bieliauskas; Raymond R Tubbs; Chris M Bacon; Camellia Eshoa; Kathryn Foucar; Sarah E Gibson; Steven H Kroft; Aliyah R Sohani; Steven H Swerdlow; James R Cook
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Epstein-Barr virus-positive diffuse large B-cell lymphoma carrying a t(9;14)(p13;q32) translocation.

Authors:  Hitoshi Ohno; Momoko Nishikori; Hironori Haga; Kotaro Isoda
Journal:  Int J Hematol       Date:  2009-05-12       Impact factor: 2.490

3.  PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).

Authors:  Kazuyuki Sato; Hirotaka Sakai; Masayuki Kato; Yuji Nishio; Yuka Tsuruoka; Yu Uemura; Satoshi Yokoi; Tasuku Saito; Manabu Matsunawa; Yoshinori Suzuki; Yasushi Isobe; Yasuyuki Inoue; Masatomo Takahashi; Ikuo Miura
Journal:  Int J Hematol       Date:  2015-01-30       Impact factor: 2.490

4.  Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen MacNamara; Chris M Bacon; Aliyah R Sohani; Steven H Swerdlow; James R Cook
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

5.  Low-grade B-Cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements.

Authors:  Tracy I George; Joanna E Wrede; Charles D Bangs; Athena M Cherry; Roger A Warnke; Daniel A Arber
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

6.  CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Authors:  Elaine Y Chung; James N Psathas; Duonan Yu; Yimei Li; Mitchell J Weiss; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

7.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen P MacNamara; Nadine S Aguilera; Steven H Swerdlow; James R Cook
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

9.  An unusual case of Epstein-Barr virus-positive large B-cell lymphoma lacking various B-cell markers.

Authors:  Shin-Ichi Nakatsuka; Chikao Yutani; Masako Kurashige; Masaharu Kohara; Teruaki Nagano; Takayoshi Goto; Hiroyuki Takatsuka; Hidetaka Ifuku; Eiichi Morii
Journal:  Diagn Pathol       Date:  2017-01-31       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.